188 related articles for article (PubMed ID: 36073756)
1. Lysosome-targeted cyclometalated iridium(III) complexes: JMJD inhibition, dual induction of apoptosis, and autophagy.
Lu JJ; Ma XR; Xie K; Chen MR; Huang B; Li RT; Ye RR
Metallomics; 2022 Sep; 14(9):. PubMed ID: 36073756
[TBL] [Abstract][Full Text] [Related]
2. Mitochondria-targeted cyclometalated iridium (III) complexes: Dual induction of A549 cells apoptosis and autophagy.
Chen L; Tang H; Chen W; Wang J; Zhang S; Gao J; Chen Y; Zhu X; Huang Z; Chen J
J Inorg Biochem; 2023 Dec; 249():112397. PubMed ID: 37844533
[TBL] [Abstract][Full Text] [Related]
3. 8-Hydroxyquinoline-modified ruthenium(II) polypyridyl complexes for JMJD inhibition and photodynamic antitumor therapy.
Ma X; Lu J; Yang P; Zhang Z; Huang B; Li R; Ye R
Dalton Trans; 2022 Sep; 51(36):13902-13909. PubMed ID: 36040403
[TBL] [Abstract][Full Text] [Related]
4. Cyclometalated iridium(III) complexes as mitochondria-targeted anticancer and antibacterial agents to induce both autophagy and apoptosis.
Chen BB; Pan NL; Liao JX; Huang MY; Jiang DC; Wang JJ; Qiu HJ; Chen JX; Li L; Sun J
J Inorg Biochem; 2021 Jun; 219():111450. PubMed ID: 33826973
[TBL] [Abstract][Full Text] [Related]
5. Novel heterobimetallic Ir(III)-Re(I) complexes: design, synthesis and antitumor mechanism investigation.
Lu JJ; Ma XR; Xie K; Yang PX; Li RT; Ye RR
Dalton Trans; 2022 May; 51(20):7907-7917. PubMed ID: 35535974
[TBL] [Abstract][Full Text] [Related]
6. The cyclometalated iridium (III) complex based on 9-Anthracenecarboxylic acid as a lysosomal-targeted anticancer agent.
Liu L; Chen J; Wang MM; Huang Y; Qian Y; Xue X; Su Z; Liu HK
J Inorg Biochem; 2022 Oct; 235():111913. PubMed ID: 35905643
[TBL] [Abstract][Full Text] [Related]
7. Induction of apoptosis in SGC-7901 cells by iridium(III) complexes via endoplasmic reticulum stress-mitochondrial dysfunction pathway.
Wang J; Liu H; Wu X; Shi C; Li W; Yuan Y; Liu Y; Xing D
J Biol Inorg Chem; 2022 Aug; 27(4-5):455-469. PubMed ID: 35817878
[TBL] [Abstract][Full Text] [Related]
8. Mitochondria-targeted cyclometalated iridium-β-carboline complexes as potent non-small cell lung cancer therapeutic agents.
Chen J; Guo X; Li D; Tang H; Gao J; Yu W; Zhu X; Sun Z; Huang Z; Chen L
Metallomics; 2023 Jun; 15(6):. PubMed ID: 37204038
[TBL] [Abstract][Full Text] [Related]
9. Anticancer effect evaluation in vitro and in vivo of iridium(III) polypyridyl complexes targeting DNA and mitochondria.
Zhang H; Tian L; Xiao R; Zhou Y; Zhang Y; Hao J; Liu Y; Wang J
Bioorg Chem; 2021 Oct; 115():105290. PubMed ID: 34426145
[TBL] [Abstract][Full Text] [Related]
10. Identification of two mitochondrial-targeting cyclometalated iridium(III) complexes as potent anti-glioma stem cells agents.
Peng W; Hegazy AM; Jiang N; Chen X; Qi HX; Zhao XD; Pu J; Ye RR; Li RT
J Inorg Biochem; 2020 Feb; 203():110909. PubMed ID: 31689591
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and antitumor mechanism investigation of iridium(III) complexes conjugated with ibuprofen.
Chen SQ; Lu XY; Zhu LY; Zhu H; Li RT; Ye RR
J Inorg Biochem; 2024 Aug; 257():112596. PubMed ID: 38759264
[TBL] [Abstract][Full Text] [Related]
12. Iridium(III) complexes conjugated with naproxen exhibit potent anti-tumor activities by inducing mitochondrial damage, modulating inflammation, and enhancing immunity.
Xie K; Lu XY; Zhu H; Zhu LY; Li RT; Ye RR
Dalton Trans; 2024 May; 53(20):8772-8780. PubMed ID: 38712840
[TBL] [Abstract][Full Text] [Related]
13. Anticancer and antibacterial activity in vitro evaluation of iridium(III) polypyridyl complexes.
Yi QY; Zhang WY; He M; Du F; Wang XZ; Wang YJ; Gu YY; Bai L; Liu YJ
J Biol Inorg Chem; 2019 Mar; 24(2):151-169. PubMed ID: 30564887
[TBL] [Abstract][Full Text] [Related]
14. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents.
Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z
Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192
[TBL] [Abstract][Full Text] [Related]
15. Targeted liposomes encapsulated iridium(III) compound greatly enhance anticancer efficacy and induce cell death via ferroptosis on HepG2 cells.
Chen J; Li W; Li G; Liu X; Huang C; Nie H; Liang L; Wang Y; Liu Y
Eur J Med Chem; 2024 Feb; 265():116078. PubMed ID: 38141286
[TBL] [Abstract][Full Text] [Related]
16. Cyclometalated iridium(III) dithioformic acid complexes as mitochondria-targeted imaging and anticancer agents.
Wu Y; Liu J; Shao M; Zhang P; Song S; Yang G; Liu X; Liu Z
J Inorg Biochem; 2022 Aug; 233():111855. PubMed ID: 35576884
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and mitochondria-localized iridium (III) complexes induce cell death through pyroptosis and ferroptosis pathways.
Hu H; Zhang F; Sheng Z; Tian S; Li G; Tang S; Niu Y; Yang J; Liu Y
Eur J Med Chem; 2024 Mar; 268():116295. PubMed ID: 38437750
[TBL] [Abstract][Full Text] [Related]
18. Mitochondria-targeted artesunate conjugated cyclometalated iridium(iii) complexes as potent anti-HepG2 hepatocellular carcinoma agents.
Ye RR; Peng W; Chen BC; Jiang N; Chen XQ; Mao ZW; Li RT
Metallomics; 2020 Jul; 12(7):1131-1141. PubMed ID: 32453319
[TBL] [Abstract][Full Text] [Related]
19. Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents.
Yang Y; Guo L; Tian Z; Gong Y; Zheng H; Zhang S; Xu Z; Ge X; Liu Z
Inorg Chem; 2018 Sep; 57(17):11087-11098. PubMed ID: 30133276
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity studies of iridium (III) polypyridine complexes-loaded liposomes against gastric tumor cell in vitro.
Xie FL; Huang ZT; Bai L; Zhu JW; Xu HH; Long QQ; Guo QF; Wu Y; Liu SH
J Inorg Biochem; 2021 Dec; 225():111603. PubMed ID: 34564032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
